Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants (DOXIE)

January 24, 2024 updated by: Anup Katheria, M.D., Sharp HealthCare
This study is being conducted to compare the incidence of preterm infants (up to 28+6 weeks GA) who achieve a peripheral oxygen saturation of 80 percent by 5 minutes of life (MOL) given mask CPAP/PPV with an FiO2 of 1.0 during DCC for 90 seconds (HI Group) to infants given mask CPAP/PPV with an FiO2 of .30 during DCC for 90 seconds (LO Group).

Study Overview

Detailed Description

Prenatal consent will be obtained on infant's with estimated gestational age up to 28+6 weeks. Shortly before delivery, infant's will be randomly assigned to receive either Low oxygen concentration (FiO2 .30) OR High oxygen concentration (FiO2 1.0) during 90 seconds of delayed cord clamping.

Randomization and intervention will remain blinded to the clinical care team during the entire study period. The research team member will open a randomization card when notified of a subject's impending birth, review the protocol with the obstetric provider performing the procedure, set-up the sterile stabilization bed, and note the time it takes from delivery until the clamping and cutting of the umbilical cord in both groups.

The research team member will set the oxygen blender as indicated by the randomization card and cover the blender to blind the FiO2 setting. The research team member will not be involved in the clinical care of the infant. The oxygen blender will be concealed from the clinical care team to ensure resuscitation maneuvers will not be biased.

Data will be submitted to the statistician, who will remain blinded to the intervention for the duration of the study.

At delivery, the infant will be placed on a platform that allows the infant to be close to the mother and the umbilical cord to remain intact for DCC. These beds are equipped with an oxygen blender, humidifier, t-piece resuscitator with mask, necessary to provide CPAP/PPV. At some centers the bed will be equipped with a radian warmer (Ceramotherm, Wyer GmbH, Germany) to maintain thermoregulation on the infant during delayed cord clamping.

If an infant is randomized to the DCC and Low Oxygen concentration (DCC LO group), the following procedure will ensue:

During delayed cord clamping, the infant will be gently stimulated by drying the infant with a sterile towel and provide CPAP by 30 seconds of life. During delayed cord clamping, breathing assistance with CPAP of 5 cm H20 and a FiO2 0.3 will be provided.

If an infant is randomized to the DCC and High Oxygen concentration (DCC HI group), the following procedure will ensue:

During delayed cord clamping, the infant will be gently stimulated by drying the infant with a sterile towel and provide CPAP by 30 seconds of life. During delayed cord clamping, breathing assistance with CPAP of 5 cm H20 and a FiO2 1.0 will be provided.

Patency of the airway in both groups will be assessed by a Colorimetric CO2 detector. Lack of color change will indicate that the airway is not patent (obstructed), the pressure is not sufficient to expand the lungs, there was excessive air leak, or there was no or inadequate pulmonary blood flow. If there is no color change, the neonatal provider will reposition and reattempt to open the airway, if no improvement they will initiate PPV (starting PIP of 20 cm H20) by 60 seconds of life. Cord clamping will occur at 90 seconds or greater and the infant will be transferred to a standard neonatal warmer and resuscitated per NRP guidelines.

Additionally, when available heart rate data will be collected using a non-invasive dry-electrode monitor, (NeoBeat, Laerdal Medical, Stavanger, Norway) and applied over the infant's chest or abdomen to provide continuous display of heart rate during 90 seconds of DCC.

Pulse oximetry, ECG sensors and Near-Infrared Spectroscopy (NIRS) sensors will be applied after cord clamping. The NIRS sensor will be placed on the infant's forehead. Cerebral StO2, SpO2, blood pressure (once in the NICU) and Heart rate will be recorded every two seconds and linked with other variables. These variables will continue to be recorded for the first 24 hours of life.

Blood sample will be collected at two different time points: Cord blood sample (T1: Cord blood collected after the cord is cut) and at 2 hours of life or NICU admission (T2). This is extra few drops of blood that is drawn from the baby for medical purposes (cord blood from cord gases and admission blood work up).

Samples will be tested for oxidized and reduced glutathione which are the most reliable and comprehensive biomarkers of oxidative stress.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • California
      • Davis, California, United States, 95618
        • Recruiting
        • University of California Davis
        • Contact:
      • San Diego, California, United States, 92123
        • Recruiting
        • Sharp Mary Birch Hospital for Women and Newborns
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 6 months (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • up to 28+6 weeks Gestational age
  • Single and Multiple pregnancy
  • All modes of delivery (vaginally or caesarean section)

Exclusion Criteria:

  • Parents decline consent
  • Congenital anomalies of the newborn
  • Bleeding Accreta
  • Monochorionic multiples with evidence of TTTS
  • Fetal or maternal risk (i.e. compromise)
  • Preterm Premature Rupture of Membranes prior to 20 weeks gestation
  • Parents request no resuscitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: DCC and Low Oxygen Concentration
During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
Other Names:
  • DCC with Low Oxygen concentration
  • DCC LO group
Experimental: DCC and High Oxygen Concentration
During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
Other Names:
  • DCC with High Oxygen concentration
  • DCC HI group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of administration of oxygen during delayed cord clamping and it's impact on the incidence of preterm infants (up to 28 +6 weeks) who achieve a peripheral oxygen saturation of 80 percent by 5 minutes of life
Time Frame: by 5 minutes of life
To assess the feasibility and compare the incidence of preterm infants (up to 28+6 weeks GA) who achieve a peripheral oxygen saturation of 80 percent by 5 MOL given mask CPAP/PPV with an FiO2 of 1.0 during DCC for 90 seconds (HI Group) to infants given mask CPAP/PPV with an FiO2 of .30 during DCC for 90 seconds (LO Group).
by 5 minutes of life

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All Grade IVH
Time Frame: Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)
Any Intraventricular Hemorrhage (grades 1-4)
Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)
Frequency of Grade III and IV intraventricular hemorrhage
Time Frame: Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)
Intraventricular hemorrhages (grades 3-4) (bleeding in the brain parenchyma and/or ventricular dilation
Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)
Resuscitation interventions
Time Frame: In the first 10 minutes of life
Resuscitation interventions including intubation, chest compressions, medications
In the first 10 minutes of life
Changes in heart rate (BPM) in the first 10 minutes of life
Time Frame: In the first 10 minutes of life
Changes in heart rate (BPM) in the first 10 minutes of life
In the first 10 minutes of life

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Inspired fractional oxygen (FiO2)
Time Frame: In the first 10 minutes of life
Changes in Inspired fractional oxygen (FiO2)
In the first 10 minutes of life
Duration of Hypoxia
Time Frame: The first 10 minutes of life in the delivery room
Duration of Hypoxia (defined as oxygen saturation<25th percentile of target ranges defined by Dawson et al.) in the first 10 minutes after birth
The first 10 minutes of life in the delivery room
Duration of Hyperoxia
Time Frame: The first 10 minutes of life in the delivery room
Duration of Hyperoxia (defined as oxygen saturation>95%) in the first 10 minutes after birth
The first 10 minutes of life in the delivery room
Changes in Mean airway pressure, MAP (cm H20)
Time Frame: In the first 10 minutes of life
Changes in Mean airway pressure, MAP (cm H20)
In the first 10 minutes of life
Duration of Positive Pressure Ventilation
Time Frame: The first 10 minutes of life in the delivery room
Duration of positive pressure ventilation
The first 10 minutes of life in the delivery room
Blood pressures in the first 24 hours of life
Time Frame: In the first 24 hours of life
Blood pressures every hour in the first 24 hours of life
In the first 24 hours of life
Cerebral tissue oxygenation in the first 24 hours of life
Time Frame: In the first 24 hours of life
Cerebral tissue oxygenation in the first 24 hours of life
In the first 24 hours of life
Average oxygen saturation in the first 5 minutes after birth
Time Frame: by 5 minutes of life
Oxygen saturation in the first 5 minutes after birth
by 5 minutes of life
Average Heart rate in the first 5 minutes after birth
Time Frame: by 5 minutes of life
Heart rate in the first 5 minutes after birth
by 5 minutes of life
Intubation in the Delivery room or Neonatal Intensive Care Unit (NICU)
Time Frame: Birth through study completion at discharge, up to 6 months of corrected gestational age
Intubation in the Delivery room or Neonatal Intensive Care Unit (NICU)
Birth through study completion at discharge, up to 6 months of corrected gestational age
Lowest and Highest Hemoglobin and/or Hematocrit
Time Frame: First 24 hours of life
Hemoglobin and/or Hematocrit levels (before transfusion)
First 24 hours of life
Mean arterial blood pressure
Time Frame: First 24 hours of life
Mean arterial blood pressure (collected hourly)
First 24 hours of life
Medication for Low Blood Pressure
Time Frame: First 24 hours of life
Medication for Low Blood Pressure (e.g. hydrocortisone or pressors)
First 24 hours of life
CRIB-II (Clinical Risk Index for Babies)
Time Frame: First 12 hours of life
CRIB-II (Clinical Risk Index for Babies)
First 12 hours of life
Duration of mechanical ventilation and/or CPAP
Time Frame: Birth through study completion at discharge, up to 6 months of corrected gestational age
Number of days on mechanical ventilation and/or CPAP
Birth through study completion at discharge, up to 6 months of corrected gestational age
Surfactant administration
Time Frame: Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Surfactant administration
Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Number of RBC Transfusions since birth
Time Frame: First 10 days after birth
Number of RBC Transfusions since birth
First 10 days after birth
Patent Ductus Arteriosus requiring pharmacological or surgical treatment
Time Frame: Through study completion at discharge, up to 6 months of corrected gestational age
Patent Ductus Arteriosus requiring pharmacological or surgical treatment
Through study completion at discharge, up to 6 months of corrected gestational age
Spontaneous Intestinal Perforation (SIP) requiring surgery or peritoneal drain
Time Frame: Through study completion at discharge, up to 6 months of corrected gestational age
Spontaneous Intestinal Perforation (SIP) requiring surgery or peritoneal drain
Through study completion at discharge, up to 6 months of corrected gestational age
Necrotizing Enterocolitis (Modified Bell's stage 2-3)
Time Frame: Through study completion at discharge, up to 6 months of corrected gestational age
Necrotizing Enterocolitis (Modified Bell's stage 2-3)
Through study completion at discharge, up to 6 months of corrected gestational age
Bronchopulmonary Dysplasia (mode of respiratory support administered at 36 weeks postmenstrual age; as defined and categorized in; Jensen, Dysart, Gantz, et al: Defining Bronchopulmonary Dysplasia) http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6775872/
Time Frame: Hospital course until 36 weeks PMA
Bronchopulmonary Dysplasia (mode of respiratory support administered at 36 weeks postmenstrual age; as defined and categorized in; Jensen, Dysart, Gantz, et al: Defining Bronchopulmonary Dysplasia) http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6775872/
Hospital course until 36 weeks PMA
Severe ROP (stage 3 or treated with laser or bevacizumab)
Time Frame: After the intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Severe ROP (stage 3 or treated with laser or bevacizumab)
After the intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Combined outcome of severe IVH and/or death
Time Frame: Through study completion at death or discharge, up to 6 months of corrected gestational age
Combined outcome of severe IVH and/or death
Through study completion at death or discharge, up to 6 months of corrected gestational age
Death
Time Frame: Through study completion at death or discharge, up to 6 months of corrected gestational age
Death
Through study completion at death or discharge, up to 6 months of corrected gestational age
SVC Flow
Time Frame: 6 hours of life
Superior Vena Cava flow by echocardiography
6 hours of life
RVO
Time Frame: 6 hours of life
Right Ventricular output by echocardiography
6 hours of life
Left Ventricular Output
Time Frame: 6 hours of life
Left Ventricular output by echocardiography
6 hours of life
Cognitive Composite Score
Time Frame: 24 months corrected age
Composite Score (cognitive 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition
24 months corrected age
Language Composite Score
Time Frame: 24 months corrected age
Composite Score (language 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition
24 months corrected age
Motor Composite Score
Time Frame: 24 months corrected age
Composite Score (motor 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition
24 months corrected age
Cerebral Palsy
Time Frame: 24 months corrected age
As assessed by Gross Motor Function Classification System (GMFCS) Levels 1-5
24 months corrected age
Neurodevelopmental Outcome at 2 Years of Age
Time Frame: 22-26 months corrected age
Overall and Domain Scores- Ages and Stages, 3rd ed. Questionnaire
22-26 months corrected age
Pulsatility Index
Time Frame: 6 hours of life
Pulsatility index calculated from Doppler of the Middle Cerebral Artery
6 hours of life
Resistive Index
Time Frame: 6 hours of life
Resistive index calculated from Doppler of the Middle Cerebral Artery
6 hours of life
Changes in cerebral oxygenation saturation, StO2 (%)
Time Frame: In the first 10 minutes of life
Changes in cerebral oxygenation saturation, StO2 (%)
In the first 10 minutes of life
Changes in SpO2 (%) in the first 10 minutes of life
Time Frame: In the first 10 minutes of life
Changes in SpO2 (%) in the first 10 minutes of life
In the first 10 minutes of life
Inhaled Nitric Oxide
Time Frame: Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Use of Inhaled Nitric Oxide for Respiratory failure or Pulmonary Hypertension
Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age
Glutathione (GSH/GSSG ratio)
Time Frame: from birth up to NICU admission or in the first 2 hours of life
Assessment of oxidative biomarkers from birth up to 2 hours of life
from birth up to NICU admission or in the first 2 hours of life
Thermoregulation
Time Frame: from 5 minutes of life up to NICU admission in the first 2 hours of life
Assessment of thermoregulation (axillary temperatures measured in degrees Celsius) during delayed cord clamping on extremely low gestational infants
from 5 minutes of life up to NICU admission in the first 2 hours of life
Rate of Early Onset Sepsis
Time Frame: From birth up to 72 hours of life
assessment of early onset sepsis with a positive blood or CSF culture at </= 72 HOL
From birth up to 72 hours of life
Rate of Late Onset Sepsis
Time Frame: From > 72 hours of life through study completion at death or discharge, up to 6 months of corrected gestational age
assessment of late onset sepsis with a positive blood or CSF culture at > 72 HOL
From > 72 hours of life through study completion at death or discharge, up to 6 months of corrected gestational age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anup Katheria, MD, Sharp HealthCare

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2021

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

May 27, 2020

First Submitted That Met QC Criteria

May 29, 2020

First Posted (Actual)

June 2, 2020

Study Record Updates

Last Update Posted (Estimated)

January 25, 2024

Last Update Submitted That Met QC Criteria

January 24, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be made available per NICHD requirements (National Institute of Child Health and Human Development)

IPD Sharing Time Frame

2 years after primary publication

IPD Sharing Access Criteria

An archived dataset with documentation will be made available for additional users by outside investigators, in collaboration with the study investigators. We will work with NICHD program staff to develop a broad data sharing plan over time.

IPD Sharing Supporting Information Type

  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Insufficiency

Clinical Trials on Delayed Cord Clamping with Low Oxygen concentration

3
Subscribe